Medicare AdvantageCoverageMedium impact
MA08.045m, Tocilizumab and Related Biosimilars for Intravenous Infusion and Subcutaneous Injection
Independence Blue Cross·Rheumatology, Oncology, Internal Medicine +1 more·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated coverage, reimbursement, medical necessity criteria, and billing codes for tocilizumab (Actemra) and related biosimilar medications used for intravenous infusion and subcutaneous injection. This affects billing for rheumatoid arthritis, juvenile arthritis, and other inflammatory conditions treated with these medications.
Action Required
By July 1, 2025: Billing team must review updated medical necessity criteria for tocilizumab and biosimilar claims for Medicare Advantage patients. Update prior authorization workflows and billing system edits for any new coding requirements. Ensure providers document updated medical necessity criteria to prevent claim denials for infusion and injection services.